Bausch + Lomb Past Earnings Performance
Past criteria checks 0/6
Bausch + Lomb's earnings have been declining at an average annual rate of -74.4%, while the Medical Equipment industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 5% per year.
Key information
-74.4%
Earnings growth rate
-70.9%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 5.0% |
| Return on equity | -4.8% |
| Net Margin | -7.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
Nov 03An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued
Aug 15Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong
May 09Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate
Mar 28Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne
Feb 01Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Jan 24Bausch + Lomb acquires AcuFocus for cataract lens
Jan 17Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year
Dec 22Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops
Dec 13Bausch + Lomb: A Solid Play In Challenging Economic Times
Nov 09Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance range
Nov 02Revenue & Expenses Breakdown
How Bausch + Lomb makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,314 | -337 | 1,822 | 329 |
| 31 Dec 23 | 4,146 | -260 | 1,736 | 324 |
| 30 Sep 23 | 3,969 | -207 | 1,633 | 322 |
| 30 Jun 23 | 3,904 | -141 | 1,607 | 317 |
| 31 Mar 23 | 3,810 | -104 | 1,553 | 307 |
| 31 Dec 22 | 3,768 | 6 | 1,478 | 307 |
| 30 Sep 22 | 3,773 | 58 | 1,457 | 299 |
| 30 Jun 22 | 3,780 | 136 | 1,414 | 285 |
| 31 Mar 22 | 3,773 | 175 | 1,414 | 281 |
| 31 Dec 21 | 3,765 | 182 | 1,389 | 271 |
| 30 Sep 21 | 3,708 | -78 | 1,355 | 267 |
| 30 Jun 21 | 3,675 | -53 | 1,319 | 265 |
| 31 Mar 21 | 3,517 | -44 | 1,266 | 257 |
| 31 Dec 20 | 3,412 | -18 | 1,253 | 253 |
| 31 Dec 19 | 3,778 | 298 | 1,382 | 258 |
| 31 Dec 18 | 3,665 | 710 | 1,327 | 221 |
Quality Earnings: BLCO is currently unprofitable.
Growing Profit Margin: BLCO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLCO is unprofitable, and losses have increased over the past 5 years at a rate of 74.4% per year.
Accelerating Growth: Unable to compare BLCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLCO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.6%).
Return on Equity
High ROE: BLCO has a negative Return on Equity (-4.8%), as it is currently unprofitable.